Publications
Myogenic Progenitor Cell Lineage Specification by CRISPR/Cas9-Based Transcriptional Activators." Stem Cell Reports 14, no. 5 (2020): 755-769.
"N-cadherin is Key to Expression of the Nucleus Pulposus Cell Phenotype under Selective Substrate Culture Conditions." Scientific Reports 6 (2016).
"The next generation of CRISPR-Cas technologies and applications." Nature Reviews. Molecular Cell Biology 20, no. 8 (2019): 490-507.
"The NIH Somatic Cell Genome Editing program." Nature 592, no. 7853 (2021): 195-204.
"Nonviral In Vivo Delivery of CRISPR-Cas9 Using Protein-Agnostic, High-Loading Porous Silicon and Polymer Nanoparticles." Acs Nano 17, no. 17 (2023): 16412-16431.
"The once and future gene therapy." Nature Communications 11, no. 1 (2020).
"Orthogonal CRISPR screens to identify transcriptional and epigenetic regulators of human CD8 T cell function." bioRxiv (2023).
"PCSK9 activation promotes early atherosclerosis in a vascular microphysiological system." Apl Bioengineering 7, no. 4 (2023).
"Photoregulated gene expression in human cells with light-inducible engineered transcription factors." ASME 2012 Summer Bioengineering Conference, SBC 2012 (2012): 351-352.
"Pre-established Chromatin Interactions Mediate the Genomic Response to Glucocorticoids." Cell Systems 7, no. 2 (2018): 146-160.e7.
"Prospective isolation of chondroprogenitors from human iPSCs based on cell surface markers identified using a CRISPR-Cas9-generated reporter." Stem Cell Research & Therapy 11, no. 1 (2020).
"Pulling the genome in opposite directions to dissect gene networks." Genome Biology 19, no. 1 (2018).
"Reading frame correction by targeted genome editing restores dystrophin expression in cells from duchenne muscular dystrophy patients." Molecular Therapy 21, no. 9 (2013): 1718-1726.
"Redirecting Vesicular Transport to Improve Nonviral Delivery of Molecular Cargo." Advanced Biosystems 4, no. 8 (2020).
"Regulation of chromatin accessibility and Zic binding at enhancers in the developing cerebellum." Nat Neurosci 18, no. 5 (2015): 647-656.
"RNA-guided gene activation by CRISPR-Cas9-based transcription factors." Nature Methods 10, no. 10 (2013): 973-976.
"RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors." Nature Communications 9, no. 1 (2018).
"Robust, Durable Gene Activation In Vivo via mRNA-Encoded Activators." Acs Nano 16, no. 4 (2022): 5660-5671.
"The role of single-cell analyses in understanding cell lineage commitment." Biotechnology Journal 8, no. 4 (2013): 397-407.
"Runx2/Cbfa1 stimulates transdifferentiation of primary skeletal myoblasts into a mineralizing osteoblastic phenotype." Experimental Cell Research 300, no. 2 (2004): 406-417.
"Runx2/Cbfa1 stimulates transdifferentiation of primary skeletal myoblasts into a mineralizing osteoblastic phenotype." Exp. Cell Res. 300 (2004): 406-417.
"Runx2/Cbfa1-genetically engineered skeletal myoblasts mineralize collagen scaffolds in vitro." Biotechnology and Bioengineering 88, no. 3 (2004): 369-378.
"Runx2-genetically engineered cells for bone tissue engineering." Proceedings of the 2005 Summer Bioengineering Conference 2005 (2005): 603-604.
"Runx2-stimulated transdifferentiation of primary skeletal myoblasts into an osteoblastic mineralizing phenotype for bone tissue engineering." Transactions - 7th World Biomaterials Congress (2004).
"Scaffold-mediated lentiviral transduction for functional tissue engineering of cartilage." Proceedings of the National Academy of Sciences of the United States of America 111, no. 9 (2014): E798-E806.
"